NIH Funding Opportunities

Sidebar

Centers for HIV Structural Biology (U54 Clinical Trial Not Allowed) 

The purpose of this Funding Opportunity Announcement (FOA) is to support dynamic, multidisciplinary consortia of structural biologists, virologists, and computational scientists to resolve complex biological structures relevant to HIV prevention, treatment, and cure. The consortia are expected to leverage common resources, facilitate new collaborations, and engage and support the next generation of HIV structural biology researchers.   

RFA-AI-21-030

Application Deadline: October 13, 2021


 

Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01, Clinical Trial Not Allowed)

This funding opportunity announcement (FOA) encourages multidisciplinary teams to characterize mechanisms that impact resistance to HIV broadly neutralizing antibodies (bNAbs) and develop strategies to prevent and overcome HIV resistance to bNAbs.

RFA-A1-21-009

Application Deadline: July 30, 2021


 

Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support applications that address the RESPOND pillar of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.

RFA-AI-21-023

Application Deadline: July 30, 2021


 

Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support projects to improve use of evidence-based HIV prevention interventions among populations in priority areas identified as highly impacted by HIV. Research funded under this FOA will support the goals of the DIAGNOSE and PREVENT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative towards reducing HIV incidence. Creative, multidisciplinary approaches are needed to meet the needs of specific populations and localities.

RFA-AI-21-025

Application Deadline: July 30, 2021


 

Understanding HIV Reservoir Dynamics (P01 Clinical Trial Not Allowed)

RFA-AI-21-013

The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, Program Project applications aimed at understanding changes in the HIV reservoir over time in different cell types and tissues.  A better understanding of the mechanisms that govern HIV reservoir dynamics over time is essential to inform the development of strategies to cure HIV or control viral infection to overcome the need for life-long antiretroviral therapy.

Application Deadline: July 30, 2021


 

Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to utilize implementation science to develop, implement, and evaluate creative, multidisciplinary approaches to healthcare delivery that more effectively engage and retain individuals in HIV care and treatment so that they achieve durable viral suppression. Research funded under this FOA will support the goals of the DIAGNOSE and TREAT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative by seeking to achieve more rapid and sustained viral suppression and improved outcomes for people with HIV through better healthcare engagement.

RFA-AI-21-024

Application Deadline: August 4, 2021


 

Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33 Clinical Trial Not Allowed)

RFA-AI-21-012

This Funding Opportunity Announcement (FOA) encourages exploratory and developmental bi-phasic research. Applications are solicited to support the understanding of post-transcriptional regulation of intact and defective HIV RNA and to develop therapeutic strategies to alter RNA post-transcriptional modifications as a potential therapeutic platform for inhibiting HIV replication.

Application Deadline: August 4, 2021


Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional)

RFA-AI-21-018

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that use innovative technology to conduct epidemiologic studies of large cohorts of U.S. populations at high risk of HIV acquisition: men who have sex with men (MSM), people who inject drugs (PWID), and transgender women and men, focusing especially on the minority and age groups at highest risk of HIV transmissions. The major goal is to support investigators who will use innovative electronic methods to recruit and retain large samples of persons at high risk of HIV acquisition, comparing those who become HIV-positive to those who do not, and optionally to develop and test digitally-delivered interventions that promote HIV risk reduction to reduce HIV-incidence.

Application Deadline: August 4, 2021

At a Glance